EPCAM and neoplasm: On the other hand, researchers found that catumaxomab as adjuvant therapy could induce T cell activation and migration to peripheral tissues against gastric cancer, consequently leading to secondary antitumor immune responses to various tumor antigens other than EpCAM [146].